Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials
Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials. // Gastroenterology. – URL: https://www.sciencedirect.com/science/article/pii/S0016508526077747?dgcid=rss_sd_all
Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials. Gastroenterology. https://www.sciencedirect.com/science/article/pii/S0016508526077747?dgcid=rss_sd_all
“Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials.” Gastroenterology.
@article{article46539,
title = {Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials},
journal = {Gastroenterology},
url = {https://www.sciencedirect.com/science/article/pii/S0016508526077747?dgcid=rss_sd_all}
}